title: [AFFIRM: what we have learned ... and pending issues].
abstract: During these last years, several therapeutic strategies trials have been performed in atrial fibrillation: the goal was to compare the rhythm control strategy (restoration and maintenance of sinus rhythm) to the rate control strategy (slowing of heart rate in atrial fibrillation). The most important of these different trials is the AFFIRM study. The main conclusion of this trial is that rate control can be chosen in first intention and not only in case of failure of the rhythm control strategy. These results can not be applied to 2 categories of patients: on one hand patients with heart failure and on the other hand young patients without cardiopathy in whom the strategy of rhythm control and sinus rhythm maintenance, mainly by class I antiarrhythmic drugs, remains the better choice.
authors.affiliation: Service de cardiologie A, hôpital Européen-Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. jean-yves.le-heuzey@hop.egp.aphp.fr
authors.forename: J Y
authors.initials: JY
authors.lastname: Le Heuzey
authors.forename: E
authors.initials: E
authors.lastname: Aliot
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
authors.forename: S
authors.initials: S
authors.lastname: Kacet
authors.forename: A
authors.initials: A
authors.lastname: Leenhardt
authors.forename: P
authors.initials: P
authors.lastname: Mabo
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D000889:Anti-Arrhythmia Agents